1 available, 1 recruiting. 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Recruiting 1 |
Follow osunprotafib: new trials by email Literature Review of osunprotafib trials Research Report on osunprotafib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors ABBV-CLS-484, Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitor (TKI), Programmed Cell Death-1 (PD-1) Inhibitor - Advanced Solid Tumor Cancer | Phase 1 | Recruiting | Calico Life Sciences LLC | 248 | 2021-03-09 | 2026-06-04 |
| Expanded Access to ABBV-CLS-484 DRUG: ABBV-CLS-484 - Advanced Solid Tumor Cancer | Available | Calico Life Sciences LLC | 2024-01-03 |
Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Renal Cell (1) · Neoplasms (1) · Recurrence (1) · Squamous Cell Carcinoma of Head and Neck (1)
France (1) · Israel (1) · Japan (1) · South Korea (1) · Spain (1) · United States (1)
2023 (1)